HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CIR Model For Ingredient Assessment Piques China's Interest

This article was originally published in The Rose Sheet

Executive Summary

Regulatory authorities in developing countries, including China, are showing increasing interest in the Cosmetic Ingredient Review process, with a view to adapting it for use in their own regions, according to CIR Director Lillian Gill.

You may also be interested in...

CIR Director Gill Steps Down, Leaving Legacy Of Improved Transparency

Lillian Gill, director of the Cosmetic Ingredient Review, helped to bolster CIR’s international reputation during her four-year stint leading the group. CIR’s profile has risen as a result of her leadership, openness to outside stakeholder input and increased public interest in cosmetic ingredients’ safety overall.

Congress Proposes Public-Private Partnership For CIR

In reports accompanying draft fiscal 2016 funding bills, both House and Senate committees recommend that FDA work with industry to explore formalizing the Cosmetic Ingredient Review via a public-private partnership similar to that in place with the U.S. Pharmacopeial Convention.

European Commission Examining Prostaglandins In Cosmetics: Are They Safe? Are They Drugs?

Marketers of cosmetic products that rely on prostaglandins or their analogues to grow eyelashes – or compete against companies that use the ingredients – have until 22 October to submit information to the Commission, which will help inform an assessment by the Scientific Committee on Consumer Safety.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts